Sugi Predict

Sugi Predict / Compounds / SCHEMBL496758

SCHEMBL496758

SCHEMBL496758

O=C(O)c1cnc2ccccn12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.60
▸ RAB9A P51151 2/20 0.60
▸ EPHB3 P54753 1/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.51
▸ ADORA2A P29274 3/20 0.51
▸ PTGS1 P23219 1/20 0.47
▸ PTGS2 P35354 1/20 0.47
▸ KIT P10721 1/20 0.47
▸ DDR1 Q08345 1/20 0.47
▸ DDR2 Q16832 1/20 0.47
▸ HAT1 O14929 2/20 0.46
▸ EP300 Q09472 2/20 0.46
▸ TGFBR1 P36897 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ GLA P06280 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ SLC27A1 Q6PCB7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21834227 0.98 NPC1 (0.59) NPC1RAB9AEPHB3NPSR1ADORA2A
SCHEMBL3836508 0.86 NPC1 (0.57) NPC1RAB9AEPHB3NPSR1ADORA2A
SCHEMBL11266749 0.84 NPC1 (0.78) NPC1RAB9AEPHB3NPSR1ADORA2A
SCHEMBL1355332 0.84 NPC1 (0.76) NPC1RAB9AEPHB3NPSR1ADORA2A
SCHEMBL2017759 0.84 NPC1 (0.59) NPC1RAB9AEPHB3NPSR1ADORA2A
SCHEMBL3549382 0.84 NPC1 (0.59) NPC1RAB9AEPHB3NPSR1ADORA2A
SCHEMBL14743372 0.84 NPC1 (0.63) NPC1RAB9AEPHB3NPSR1ADORA2A
Hydrochloric Acid SCHEMBL14746375 0.82 NPC1 (0.61) NPC1RAB9AEPHB3NPSR1ADORA2A
Hydrochloric Acid SCHEMBL29440777 0.82 NPC1 (0.57) NPC1RAB9AEPHB3NPSR1ADORA2A
SCHEMBL14756611 0.81 NPC1 (0.53) NPC1RAB9AEPHB3NPSR1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12344623-B2 Thiazolopyridine derivatives as adenosine receptor antagonists DOMAIN THERAPEUTICS SA (FR) 2025-07-01 — — US claimed
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 — — CN claimed
EP-4214207-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1st Biotherapeutics, Inc. (KR) 2023-07-26 — — EP claimed
CN-115998630-B Hair-blacking essence and preparation method thereof 北京普世安生物科技有限公司 2023-06-06 — — CN claimed
CN-115998630-A Hair-blacking essence and preparation method thereof 北京普世安生物科技有限公司 2023-04-25 — — CN claimed
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP claimed
EP-2903978-B1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2022-12-07 — — EP claimed
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 — — US claimed
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2022-09-27 — — US claimed
US-20220119412-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-04-21 — — US claimed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 — — WO claimed
EP-2125760-A2 THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-12-02 — — EP claimed
WO-2009133522-A1 PIPERIDINE AND PYRROLIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2009-11-05 — — WO claimed
EP-2094690-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-09-02 — — EP claimed
EP-2079690-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 — — EP claimed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 — — WO claimed
WO-2008139416-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-11-20 — — WO claimed
WO-2008117241-A2 THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-10-02 — — WO claimed
WO-2008081399-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-07-10 — — WO claimed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344623-B2 Thiazolopyridine derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 NPC1 944/4885RAB9A 2761/4885EPHB3 1130/4885
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 NPC1 1078/4885RAB9A 3169/4885EPHB3 1985/4885
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 NPC1 1208/4885RAB9A 3458/4885EPHB3 1932/4885
US-20220119412-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 NPC1 944/4885RAB9A 2761/4885EPHB3 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.